Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer

Targeted Oncology ◽

10.1007/s11523-012-0241-x ◽

2012 ◽

Vol 8 (4) ◽

pp. 237-242 ◽

Author(s):

Katsuhiko Shimizu ◽

Takuro Yukawa ◽

Yuji Hirami ◽

Riki Okita ◽

Shinsuke Saisho ◽

...

Keyword(s):

Lung Cancer ◽

Primary Tumor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Metastatic Lymph Node ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Mutation Status

Download Full-text

Egfr-Tyrosine Kinase Inhibitor Treatment Beyond Progression in Long-Term Responders to Erlotinib in Advanced Non-Small Cell Lung Cancer: Relevance of Egfr Mutation Status

Annals of Oncology ◽

10.1016/s0923-7534(20)33810-2 ◽

2012 ◽

Vol 23 ◽

pp. ix440

Author(s):

M. Faehling ◽

R. Eckert ◽

T. Kamp ◽

J. Sträter ◽

G. Ott ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Mutation Status ◽

Treatment Beyond Progression ◽

Inhibitor Treatment

Download Full-text

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-1126 ◽

2019 ◽

Vol 25 (22) ◽

pp. 6644-6652 ◽

Author(s):

Jhanelle E. Gray ◽

Isamu Okamoto ◽

Virote Sriuranpong ◽

Johan Vansteenkiste ◽

Fumio Imamura ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Line Treatment ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Egfr Mutated ◽

First Line Treatment

Download Full-text

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

The Korean Journal of Internal Medicine ◽

10.3904/kjim.2016.190 ◽

2017 ◽

Vol 32 (3) ◽

pp. 422-428 ◽

Author(s):

Yong Won Choi ◽

Jin-Hyuk Choi

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Epidermal Growth

Download Full-text

481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy

Annals of Oncology ◽

10.1093/annonc/mdw594.045 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

K. Nakagawa ◽

J.C-H. Yang ◽

K. Park ◽

Y. Ohe ◽

Y-L. Wu ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Stage Iv ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Phase 3 ◽

Epidermal Growth

Download Full-text

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation

Lung Cancer ◽

10.1016/j.lungcan.2015.09.025 ◽

2015 ◽

Vol 90 (3) ◽

pp. 477-483 ◽

Author(s):

Tatsuya Yoshida ◽

Kiyotaka Yoh ◽

Seiji Niho ◽

Shigeki Umemura ◽

Shingo Matsumoto ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Lung Cancer Patients ◽

Inhibitor Treatment

Download Full-text

Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation–Positive Non–Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.02.006 ◽

2018 ◽

Vol 13 (5) ◽

pp. e83-e84 ◽

Author(s):

Christopher Hoyle ◽

Matthew Dyer

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation–Positive Non–Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.02.017 ◽

2018 ◽

Vol 13 (5) ◽

pp. e84-e85

Author(s):

Bin Wu

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Tyrosine Kinase Inhibitor Therapy

Download Full-text

Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8084 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8084-8084 ◽

Author(s):

Keunchil Park ◽

Jong-Seok Lee ◽

Ki Hyeong Lee ◽

Joo-Hang Kim ◽

Young Joo Min ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Safety And Efficacy

Download Full-text

Does the Adjuvant Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Change the Natural History of Resected EGFR Mutation-Positive Non-Small Cell Lung Cancer? Is it for Prime Time?

SSRN Electronic Journal ◽

10.2139/ssrn.3967074 ◽

2021 ◽

Author(s):

Hyun Ae Jung ◽

Jinyeong Lim ◽

Se-Hoon Lee ◽

Je-Gun Joung ◽

Yeong Jeong Jeon ◽

...

Keyword(s):

Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor ◽

Epidermal Growth

Download Full-text

Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation

Investigational New Drugs ◽

10.1007/s10637-018-0586-9 ◽

2018 ◽

Vol 36 (4) ◽

pp. 715-717 ◽

Author(s):

Midori Tanaka ◽

Hidenobu Ishii ◽

Hayato Moribuchi ◽

Yoshiko Naito ◽

Norikazu Matsuo ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Tyrosine Kinase Inhibitor ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Egfr Tyrosine Kinase Inhibitor

Download Full-text